The topical antifungals market size has grown strongly in recent years. It will grow from $6.02 billion in 2025 to $6.42 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to limited topical antifungal options, high incidence of dermatophyte infections, reliance on hospital pharmacies, low consumer awareness of fungal infections, preference for conventional formulations.
The topical antifungals market size is expected to see strong growth in the next few years. It will grow to $8.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of azoles and allylamines innovations, increasing home healthcare adoption, growth of online pharmacy platforms, rising demand for patient-friendly formulations like creams and sprays, expansion of pharmaceutical company investments in dermatology. Major trends in the forecast period include rising prevalence of skin fungal infections, increasing preference for topical over systemic treatments, development of novel formulations and delivery systems, growing awareness of home healthcare and self-medication, expansion of online pharmacies and e-commerce distribution channels.
The increasing prevalence of skin diseases is expected to drive the growth of the topical antifungals market in the coming years. Skin diseases are conditions that affect the skin’s health, appearance, or function, including irritation, inflammation, and infections. The rise in skin diseases is largely attributed to greater exposure to environmental pollutants and ultraviolet (UV) radiation, which can damage the skin and trigger various dermatological conditions. Topical antifungals are used in the treatment of skin diseases as they deliver targeted action against fungal pathogens, limit systemic exposure, reduce the risk of side effects, and support faster healing of affected areas. For example, in March 2023, according to the World Health Organization, a Switzerland-based health organization, skin conditions were estimated to affect around 1.8 billion people globally at any given time. Therefore, the growing prevalence of skin diseases is driving the growth of the topical antifungals market.
Major companies operating in the topical antifungals market are focusing on developing innovative formulations, such as histone deacetylase (HDAC) inhibitors, to improve therapeutic effectiveness, address antifungal resistance, and enhance penetration into the nail bed for the treatment of onychomycosis. HDAC inhibitors are compounds that inhibit histone deacetylase enzymes, which are responsible for removing acetyl groups from histone proteins. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis, a widespread fungal nail infection. VTR-297 is a small-molecule HDAC inhibitor with antifungal properties, originally isolated from the bacterial species Streptomyces hygroscopicus and initially identified as an antifungal antibiotic.
In January 2023, Eris Lifesciences Ltd., an India-based pharmaceutical company focused on branded formulations, acquired nine dermatology brands, including topical antifungals such as Onabet and Luligee, from Glenmark Pharmaceuticals Ltd. for an undisclosed sum. Through this acquisition, Eris Lifesciences aims to strengthen its dermatology portfolio, expand its chronic therapy offerings, and accelerate growth in high-potential skin treatment segments. Glenmark Pharmaceuticals Ltd. is an India-based pharmaceutical company involved in the development and commercialization of generic formulations, specialty drugs, and active pharmaceutical ingredients.
Major companies operating in the topical antifungals market are Pfizer Inc., Bayer AG, Novartis AG, GSK plc, Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Galderma S.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Taro Pharmaceutical Industries Ltd., Natco Pharma Ltd., Glamris Dermacare, Perrigo Company plc, Teva Pharmaceutical Industries Ltd., Viatris Inc., Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd., Abbott Laboratories, Johnson & Johnson (Janssen Consumer Health), Reckitt Benckiser Group plc, Himalaya Wellness Company, Aristo Pharmaceuticals Pvt. Ltd., Emcure Pharmaceuticals Ltd., Ajanta Pharma Ltd., Alembic Pharmaceuticals Ltd.
North America was the largest region in the topical antifungals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topical antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the topical antifungals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the topical antifungals market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials used in creams, ointments, and sprays. Segments such as azoles and allylamines are particularly impacted, with regions like Asia-Pacific, including India and China, facing higher import duties. This has led to increased production costs and pricing adjustments across pharmacies and hospitals. However, tariffs have also encouraged local manufacturing, boosting domestic API production and innovation in cost-effective formulations.
The topical antifungals market research report is one of a series of new reports that provides topical antifungals market statistics, including topical antifungals industry global market size, regional shares, competitors with a topical antifungals market share, detailed topical antifungals market segments, market trends and opportunities, and any further data you may need to thrive in the topical antifungals industry. This topical antifungals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Topical antifungals are medications applied externally to treat fungal infections affecting the skin, nails, or mucosal surfaces by inhibiting fungal growth or eliminating the fungi. They are typically used for mild to moderate infections and help reduce symptoms such as itching, redness, and inflammation.
The main product types of topical antifungals include azoles, allylamines, echinocandins, and polyenes. Azoles act by blocking the synthesis of ergosterol, an essential component of fungal cell membranes. These drugs are available in various formulations, including creams, ointments, lotions, sprays, and powders. They are mainly used to manage conditions such as dermatophyte infections, candidiasis, tinea infections, and onychomycosis. Topical antifungals are distributed through multiple channels, including pharmacies, online pharmacies, hospital pharmacies, and drugstores, and are utilized by end users such as hospitals, clinics, home healthcare settings, and pharmaceutical companies.
The topical antifungals market consists of sales of clotrimazole, terbinafine, ketoconazole, econazole, and tolnaftate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The topical antifungals market size is expected to see strong growth in the next few years. It will grow to $8.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of azoles and allylamines innovations, increasing home healthcare adoption, growth of online pharmacy platforms, rising demand for patient-friendly formulations like creams and sprays, expansion of pharmaceutical company investments in dermatology. Major trends in the forecast period include rising prevalence of skin fungal infections, increasing preference for topical over systemic treatments, development of novel formulations and delivery systems, growing awareness of home healthcare and self-medication, expansion of online pharmacies and e-commerce distribution channels.
The increasing prevalence of skin diseases is expected to drive the growth of the topical antifungals market in the coming years. Skin diseases are conditions that affect the skin’s health, appearance, or function, including irritation, inflammation, and infections. The rise in skin diseases is largely attributed to greater exposure to environmental pollutants and ultraviolet (UV) radiation, which can damage the skin and trigger various dermatological conditions. Topical antifungals are used in the treatment of skin diseases as they deliver targeted action against fungal pathogens, limit systemic exposure, reduce the risk of side effects, and support faster healing of affected areas. For example, in March 2023, according to the World Health Organization, a Switzerland-based health organization, skin conditions were estimated to affect around 1.8 billion people globally at any given time. Therefore, the growing prevalence of skin diseases is driving the growth of the topical antifungals market.
Major companies operating in the topical antifungals market are focusing on developing innovative formulations, such as histone deacetylase (HDAC) inhibitors, to improve therapeutic effectiveness, address antifungal resistance, and enhance penetration into the nail bed for the treatment of onychomycosis. HDAC inhibitors are compounds that inhibit histone deacetylase enzymes, which are responsible for removing acetyl groups from histone proteins. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis, a widespread fungal nail infection. VTR-297 is a small-molecule HDAC inhibitor with antifungal properties, originally isolated from the bacterial species Streptomyces hygroscopicus and initially identified as an antifungal antibiotic.
In January 2023, Eris Lifesciences Ltd., an India-based pharmaceutical company focused on branded formulations, acquired nine dermatology brands, including topical antifungals such as Onabet and Luligee, from Glenmark Pharmaceuticals Ltd. for an undisclosed sum. Through this acquisition, Eris Lifesciences aims to strengthen its dermatology portfolio, expand its chronic therapy offerings, and accelerate growth in high-potential skin treatment segments. Glenmark Pharmaceuticals Ltd. is an India-based pharmaceutical company involved in the development and commercialization of generic formulations, specialty drugs, and active pharmaceutical ingredients.
Major companies operating in the topical antifungals market are Pfizer Inc., Bayer AG, Novartis AG, GSK plc, Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Galderma S.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Taro Pharmaceutical Industries Ltd., Natco Pharma Ltd., Glamris Dermacare, Perrigo Company plc, Teva Pharmaceutical Industries Ltd., Viatris Inc., Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd., Abbott Laboratories, Johnson & Johnson (Janssen Consumer Health), Reckitt Benckiser Group plc, Himalaya Wellness Company, Aristo Pharmaceuticals Pvt. Ltd., Emcure Pharmaceuticals Ltd., Ajanta Pharma Ltd., Alembic Pharmaceuticals Ltd.
North America was the largest region in the topical antifungals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topical antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the topical antifungals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the topical antifungals market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials used in creams, ointments, and sprays. Segments such as azoles and allylamines are particularly impacted, with regions like Asia-Pacific, including India and China, facing higher import duties. This has led to increased production costs and pricing adjustments across pharmacies and hospitals. However, tariffs have also encouraged local manufacturing, boosting domestic API production and innovation in cost-effective formulations.
The topical antifungals market research report is one of a series of new reports that provides topical antifungals market statistics, including topical antifungals industry global market size, regional shares, competitors with a topical antifungals market share, detailed topical antifungals market segments, market trends and opportunities, and any further data you may need to thrive in the topical antifungals industry. This topical antifungals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Topical antifungals are medications applied externally to treat fungal infections affecting the skin, nails, or mucosal surfaces by inhibiting fungal growth or eliminating the fungi. They are typically used for mild to moderate infections and help reduce symptoms such as itching, redness, and inflammation.
The main product types of topical antifungals include azoles, allylamines, echinocandins, and polyenes. Azoles act by blocking the synthesis of ergosterol, an essential component of fungal cell membranes. These drugs are available in various formulations, including creams, ointments, lotions, sprays, and powders. They are mainly used to manage conditions such as dermatophyte infections, candidiasis, tinea infections, and onychomycosis. Topical antifungals are distributed through multiple channels, including pharmacies, online pharmacies, hospital pharmacies, and drugstores, and are utilized by end users such as hospitals, clinics, home healthcare settings, and pharmaceutical companies.
The topical antifungals market consists of sales of clotrimazole, terbinafine, ketoconazole, econazole, and tolnaftate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Topical Antifungals Market Characteristics
3. Topical Antifungals Market Supply Chain Analysis
4. Global Topical Antifungals Market Trends and Strategies
5. Topical Antifungals Market Analysis of End Use Industries
7. Global Topical Antifungals Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Topical Antifungals Total Addressable Market (TAM) Analysis for the Market
9. Topical Antifungals Market Segmentation
10. Topical Antifungals Market Regional and Country Analysis
11. Asia-Pacific Topical Antifungals Market
12. China Topical Antifungals Market
13. India Topical Antifungals Market
14. Japan Topical Antifungals Market
15. Australia Topical Antifungals Market
16. Indonesia Topical Antifungals Market
17. South Korea Topical Antifungals Market
18. Taiwan Topical Antifungals Market
19. South East Asia Topical Antifungals Market
20. Western Europe Topical Antifungals Market
21. UK Topical Antifungals Market
22. Germany Topical Antifungals Market
23. France Topical Antifungals Market
24. Italy Topical Antifungals Market
25. Spain Topical Antifungals Market
26. Eastern Europe Topical Antifungals Market
27. Russia Topical Antifungals Market
28. North America Topical Antifungals Market
29. USA Topical Antifungals Market
30. Canada Topical Antifungals Market
31. South America Topical Antifungals Market
32. Brazil Topical Antifungals Market
33. Middle East Topical Antifungals Market
34. Africa Topical Antifungals Market
36. Topical Antifungals Market Competitive Landscape and Company Profiles
37. Topical Antifungals Market Other Major and Innovative Companies
40. Topical Antifungals Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Topical Antifungals Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses topical antifungals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for topical antifungals? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The topical antifungals market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Azoles; Allylamines; Echinocandins; Polyenes2) By Formulation Type: Creams; Ointments; Lotions; Sprays; Powders
3) By Indication: Dermatophyte Infections; Candidiasis; Tinea Infections; Onychomycosis
4) By Distribution Channel: Pharmacies; Online Pharmacies; Hospital Pharmacies; Drug Stores
5) By End-User: Hospitals; Clinics; Home Healthcare
Subsegments:
1) By Azoles: Clotrimazole; Miconazole; Ketoconazole; Fluconazole2) By Allylamines: Terbinafine; Naftifine; Butenafine
3) By Echinocandins: Caspofungin; Micafungin; Anidulafungin
4) By Polyenes: Nystatin; Amphotericin B
Companies Mentioned: Pfizer Inc.; Bayer AG; Novartis AG; GSK plc; Macleods Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; Galderma S.A.; Aurobindo Pharma Limited; Dr. Reddy’s Laboratories; Cipla Limited; Lupin Limited; Zydus Lifesciences Ltd.; Glenmark Pharmaceuticals Ltd.; Alkem Laboratories Ltd.; Ipca Laboratories Ltd.; Taro Pharmaceutical Industries Ltd.; Natco Pharma Ltd.; Glamris Dermacare; Perrigo Company plc; Teva Pharmaceutical Industries Ltd.; Viatris Inc.; Amneal Pharmaceuticals LLC; Torrent Pharmaceuticals Ltd.; Abbott Laboratories; Johnson & Johnson (Janssen Consumer Health); Reckitt Benckiser Group plc; Himalaya Wellness Company; Aristo Pharmaceuticals Pvt. Ltd.; Emcure Pharmaceuticals Ltd.; Ajanta Pharma Ltd.; Alembic Pharmaceuticals Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Topical Antifungals market report include:- Pfizer Inc.
- Bayer AG
- Novartis AG
- GSK plc
- Macleods Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Galderma S.A.
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories
- Cipla Limited
- Lupin Limited
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Ltd.
- Alkem Laboratories Ltd.
- Ipca Laboratories Ltd.
- Taro Pharmaceutical Industries Ltd.
- Natco Pharma Ltd.
- Glamris Dermacare
- Perrigo Company plc
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Amneal Pharmaceuticals LLC
- Torrent Pharmaceuticals Ltd.
- Abbott Laboratories
- Johnson & Johnson (Janssen Consumer Health)
- Reckitt Benckiser Group plc
- Himalaya Wellness Company
- Aristo Pharmaceuticals Pvt. Ltd.
- Emcure Pharmaceuticals Ltd.
- Ajanta Pharma Ltd.
- Alembic Pharmaceuticals Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.42 Billion |
| Forecasted Market Value ( USD | $ 8.23 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
